NICE Stock Recent News

Investors interested in stocks from the Internet - Software sector have probably already heard of Nice (NICE) and VERRA MOBILITY CORP (VRRM). But which of these two stocks is more attractive to value investors?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Nice (NICE) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, NICE broke through the 200-day moving average, which suggests a long-term bullish trend.

Nice (NICE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

HOBOKEN, N.J.--(BUSINESS WIRE)-- #AI--NICE Actimize, a NICE (NASDAQ: NICE) business, today announced its information-packed agenda for ENGAGE 2025, the industry's premier financial crime and compliance industry event. To be held on June 17-18 at New York's Sheraton Times Square Hotel, NICE Actimize's ENGAGE will bring together financial institutions thought leaders and subject matter experts to discuss the technology advancements and best practices in financial crime fighting. More than 200 companies.

HOBOKEN, N.J.--(BUSINESS WIRE)-- #AI--NICE Actimize, a NICE (NASDAQ: NICE) business, today announced that its market-leading SURVEIL-X Holistic Conduct Surveillance solution is now integrated with Actimize Intelligence, powerful Generative AI capabilities designed to ensure accurate and timely detection of market abuse and conduct risks across every type of regulated employee communication, from emails and chats to traditional voice calls. Created to address the growing complexities of financial crim.

First non-immunosuppressive dual-action therapy recommended by NICE for eligible patients with IgA nephropathy, a leading cause of kidney failure 1-3 NICE's recommendation is based on clinically meaningful results from the phase-III PROTECT trial 4 ST. GALLEN, Switzerland , May 23, 2025 /PRNewswire/ -- CSL Vifor is pleased to announce that the National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending that sparsentan can be used in the NHS in England as an option to treat primary IgA nephropathy in adults with a urine protein excretion of 1.0 g/day or more, or a urine protein-to-creatinine ratio of 0.75 g/g or more.3 NICE has provided guidance to ensure that only patients responding to treatment continue.3 The decision follows authorisation from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) in April 2025.5 What this means in practice is that there is enough evidence to show that sparsentan provides benefits and value

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

NICE has a strong leadership and narrow economic moat in both business segments (CX and FCC) based on switching costs. With a revised down 7% revenue growth and ~30% free cash-flow margin, NICE slightly misses the Rule of 40, but I expect a slight re-acceleration of growth next year. Derived from a DCF model and backed by a comparison with peers, my fair value estimate is $232, about 42% above the current price of $163.4.

Zacks.com users have recently been watching Nice (NICE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.